Federica Martorana

Clinical Implications of UGT1A1 Polymorphisms in Anticancer Therapy: An Updated Review.

Journal: Pharmaceutics

Published: June 29, 2026

Synthetic data generation from population-based breast cancer registries: opportunities and limitations for survival analysis applications.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: June 27, 2026

A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with ESR1-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine Therapy.

Journal: Cancers

Published: June 03, 2026

Breast-Conserving Surgery Versus Mastectomy After Neoadjuvant Therapy: A Survival Analysis.

Journal: Annals of surgical oncology

Published: April 27, 2026

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Journal: Nature communications

Published: April 15, 2026

Revisiting Diffuse Gliomas in the Era of Precision Medicine: Molecular Insights and Therapeutic Implications.

Journal: Critical reviews in oncology/hematology

Published: April 10, 2026

Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.

Journal: Current oncology (Toronto, Ont.)

Published: February 10, 2026

Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 20, 2025

MTClin: Integrating MammaTyper® to predict neoadjuvant therapy response in HER2+ breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 22, 2025

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.

Journal: Cancers

Published: July 08, 2025

A Multicenter Real-Life Evaluation of Safety and Effectiveness of the Antibody-Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

Journal: American journal of clinical oncology

Published: May 19, 2025

Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer.

Journal: Critical reviews in oncology/hematology

Published: May 05, 2025

Clinical Implications of UGT1A1 Polymorphisms in Anticancer Therapy: An Updated Review.

Clinical Implications of UGT1A1 Polymorphisms in Anticancer Therapy: An Updated Review.

Synthetic data generation from population-based breast cancer registries: opportunities and limitations for survival analysis applications.

Synthetic data generation from population-based breast cancer registries: opportunities and limitations for survival analysis applications.

A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with ESR1-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine Therapy.

A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with ESR1-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine Therapy.

Breast-Conserving Surgery Versus Mastectomy After Neoadjuvant Therapy: A Survival Analysis.

Breast-Conserving Surgery Versus Mastectomy After Neoadjuvant Therapy: A Survival Analysis.

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Revisiting Diffuse Gliomas in the Era of Precision Medicine: Molecular Insights and Therapeutic Implications.

Revisiting Diffuse Gliomas in the Era of Precision Medicine: Molecular Insights and Therapeutic Implications.

Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.

Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.

Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.

Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.

MTClin: Integrating MammaTyper® to predict neoadjuvant therapy response in HER2+ breast cancer.

MTClin: Integrating MammaTyper® to predict neoadjuvant therapy response in HER2+ breast cancer.

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.

A Multicenter Real-Life Evaluation of Safety and Effectiveness of the Antibody-Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

A Multicenter Real-Life Evaluation of Safety and Effectiveness of the Antibody-Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer.

Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer.

MTClin: Integrating MammaTyper® to predict neoadjuvant therapy response in HER2+ breast cancer.

MTClin: Integrating MammaTyper® to predict neoadjuvant therapy response in HER2+ breast cancer.